Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375200 | 0.90 | RORC (0.42) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504495 | 0.90 | TTR (0.46) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504556 | 0.89 | LMNA (0.39) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504800 | 0.84 | MAPK14 (0.47) | — | |
| SCHEMBL1504507 | 0.84 | HDAC1 (0.44) | RORCCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1504761 | 0.79 | ALDH1A1 (0.38) | RORCCYP3A4CYP2C9CYP1A2TTR | |
| SCHEMBL1504557 | 0.78 | HDAC1 (0.45) | NPC1 | |
| SCHEMBL375794 | 0.77 | ALDH1A1 (0.41) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL30159267 | 0.77 | TTR (0.42) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1504002 | 0.77 | TTR (0.42) | RORCCYP3A4CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| CN-101675034-A | Pyridone derivatives as p38a mapk inhibitors | ASTELLAS PHARMA INC | 2010-03-17 | — | — | CN | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | RORC 861/4885CYP3A4 743/4885CYP2C9 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.